New Delhi, May 11: Natco Pharma on Wednesday announced the launch of a blood cancer drug in Indian market. The new drug is priced in the range of Rs 5,000-Rs 20,000, which is a 98 per cent lower than what it is sold in the US market.
Available at 98% discounted price than US market.
Natco Pharma has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India,the drug major said in a communiqué to the BSE.
Pomalidomide is for patients with multiple myeloma (a type of blood cancer).
Natco has priced its generic medicine 1 mg, 2 mg, and 4 mg capsules at Rs 5,000, Rs 10,000 Rs 20,000 respectively for a monthly pack of 21 capsules.
Pomalidomide is sold by Celgene Inc, in the US, under the brand name Pomalyst. Natco will market generic pomalidomide capsules under its brand name Pomalid in India.